Connect with us


Poor nations rejected more than 100 million Covid-19 vaccines over short shelf-life



Poor nations rejected greater than 100 million doses of COVID-19 vaccines distributed by the worldwide programme COVAX in December 2021, primarily attributable to their fast expiry date, UNICEF has disclosed .

Regardless of rising provides of photographs, the world continues to be a great distance off being vaccinated, with COVAX getting nearer to delivering one billion doses to a complete of almost 150 nations, a UN official pressured.

“Greater than a 100 million have been rejected simply in December alone,” Reuters quoted the Director of Provide Division at UN company, UNICEF, Etleva Kadilli, to have informed lawmakers on the European UnionParliament. 

The primary motive for rejection was the supply of doses with a brief shelf-life, she mentioned.

The UNICEF official revealed how in Nigeria, the federal authorities  destroyed expired AstraZeneca COVID-19 injections totalling 1,066,214 doses. Addressing journalists shortly earlier than getting down to destroy the vaccines on the Idu Dump web site within the Federal Capital Territory, the Govt Director of the Nationwide Main Healthcare Growth Company (NPHCDA) Dr. Faisal Shuaib, defined that the federal government took the motion to destroy the expired vaccines not solely to safeguard the well being of Nigerians, however to additionally engender belief within the COVID-19 vaccination marketing campaign.

Additionally, Kadilli disclosed that poorer nations have additionally been pressured to delay provides as a result of they’ve inadequate storage services, together with an absence of fridges for vaccines. 

The official additionally pressured that many nations additionally face excessive ranges of vaccine hesitancy and have overburdened healthcare methods.


UNICEF’s information on provides and use of delivered vaccines confirmed that 681 million shipped doses are presently saved in about 90 poorer nations, in response to CARE, a charity, which extracted the figures from a public database.

“We now have nations which can be pushing doses which can be presently accessible in direction of quarter two of 2022,” Kadilli mentioned.

“Of the 15 million doses from the EU which have been refused, three-quarters have been AstraZeneca photographs with a shelf lifetime of lower than 10 weeks upon arrival”

Greater than 30 poorer nations, together with huge states such because the Democratic Republic of Congo and Nigeria, have used fewer than half of the doses they acquired, CARE mentioned.


A spokesperson for Gavi, a vaccine alliance which co-manages COVAX, mentioned that the excessive storage stage was attributable to a surge in deliveries within the final quarter, particularly in December.


In January, 67 per cent of the inhabitants in richer nations had been absolutely vaccinated, whereas solely eight per cent in poorer nations have acquired their first dose, WHO figures present. Elevated provide caught many receiving nations unprepared.


Rich nations donating vaccines with a comparatively quick shelf life had been a “main downside” for COVAX, a WHO senior official mentioned final month.

In one other improvement, Africa’s prime public well being physique has mentioned it’s in talks with Pfizer about securing provides of its antiviral COVID-19 drugs for the continent, the Paxlovid medicine which is almost 90 per cent efficient in stopping hospitalisations and deaths.


“We’re in actually shut discussions with Pfizer to see what will be completed to make the medicine accessible on the continent and accessible on the continent, that’s, the Paxlovid medicine,” mentioned the Director of the Africa Centres for Illness Management and Prevention, John Nkengasong.


“The one approach to relieve that will probably be if we’ve got medicine like Paxlovid the place folks can take that drug and keep residence and get reduction, and that approach the burden and the constraints on the well being system will probably be restricted,” Nkengasong informed a web based information briefing.

Share this Story
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *